Cosmos Health Inc (COSM)

Apr 16, 2025, 12:45 PM EDT - 7 days ago

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Apr 9, 2025, 1:40 PM EDT - 14 days ago

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Apr 8, 2025, 10:45 AM EDT - 15 days ago

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Feb 26, 2025, 11:30 AM EST - 2 months ago

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Feb 18, 2025, 8:30 AM EST - 2 months ago

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Feb 11, 2025, 10:15 AM EST - 2 months ago

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Feb 10, 2025, 1:30 PM EST - 2 months ago

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Feb 10, 2025, 9:45 AM EST - 2 months ago

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Feb 7, 2025, 10:00 AM EST - 2 months ago

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Feb 6, 2025, 3:50 PM EST - 2 months ago

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Feb 5, 2025, 11:05 AM EST - 2 months ago

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Jan 28, 2025, 11:00 AM EST - 3 months ago

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Jan 27, 2025, 3:50 PM EST - 3 months ago

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Jan 23, 2025, 3:35 PM EST - 3 months ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

VRAX

Jan 22, 2025, 8:00 AM EST - 3 months ago

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Jan 21, 2025, 3:00 PM EST - 3 months ago

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Jan 13, 2025, 9:20 AM EST - 3 months ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

VRAX

Dec 26, 2024, 1:30 PM EST - 4 months ago

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Dec 23, 2024, 9:25 AM EST - 4 months ago

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Nov 18, 2024, 8:00 AM EST - 5 months ago

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Nov 15, 2024, 10:20 AM EST - 5 months ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Nov 12, 2024, 12:00 PM EST - 5 months ago

Cosmos Health Issues Letter to Shareholders

Nov 1, 2024, 12:30 PM EDT - 6 months ago

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Sep 25, 2024, 9:25 AM EDT - 7 months ago

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Sep 23, 2024, 12:55 PM EDT - 7 months ago

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

Sep 23, 2024, 9:00 AM EDT - 7 months ago

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Sep 19, 2024, 3:40 PM EDT - 7 months ago

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Sep 18, 2024, 1:30 PM EDT - 7 months ago

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Sep 16, 2024, 8:30 AM EDT - 7 months ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

VRAX

Sep 16, 2024, 8:30 AM EDT - 7 months ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

VRAX

Aug 23, 2024, 9:35 AM EDT - 8 months ago

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 10:20 AM EDT - 8 months ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

VRAX

Aug 20, 2024, 12:20 PM EDT - 8 months ago

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs.

Aug 20, 2024, 9:00 AM EDT - 8 months ago

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

Aug 8, 2024, 1:00 PM EDT - 9 months ago

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

Aug 6, 2024, 9:00 AM EDT - 9 months ago

Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share

Jul 25, 2024, 2:45 PM EDT - 9 months ago

Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland

Jul 25, 2024, 11:40 AM EDT - 9 months ago

Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar

Jul 24, 2024, 10:55 AM EDT - 9 months ago

Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity

Jul 18, 2024, 3:45 PM EDT - 9 months ago

Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units

Jul 10, 2024, 3:45 PM EDT - 10 months ago

Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market

Jul 9, 2024, 2:00 PM EDT - 10 months ago

Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually

Jul 1, 2024, 11:20 AM EDT - 10 months ago

Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains

Jun 27, 2024, 3:45 PM EDT - 10 months ago

Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units

Jun 18, 2024, 10:00 AM EDT - 11 months ago

Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent

Jun 13, 2024, 9:25 AM EDT - 11 months ago

Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million

May 17, 2024, 10:15 AM EDT - 1 year ago

Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand

Apr 19, 2024, 4:30 PM EDT - 1 year ago

Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K

Mar 21, 2024, 9:45 AM EDT - 1 year ago

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Mar 19, 2024, 10:10 AM EDT - 1 year ago

Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market